Denali Therapeutics Inc. (DNLI)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
73.73-1.08 (-1.44%)
At close: 4:00PM EDT
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 74.81 |
| Open | 73.90 |
| Bid | 62.00 x 3100 |
| Ask | 80.00 x 2200 |
| Day's Range | 72.11 - 74.97 |
| 52 Week Range | 22.36 - 93.94 |
| Volume | 1,704,969 |
| Avg. Volume | 522,707 |
| Market Cap | 8.935B |
| Beta (5Y Monthly) | 1.90 |
| PE Ratio (TTM) | 149.86 |
| EPS (TTM) | 0.49 |
| Earnings Date | Aug 05, 2021 - Aug 09, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 79.89 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-11% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Zacks
Denali Therapeutics (DNLI) is Overbought: Is A Drop Coming?
Denali Therapeutics (DNLI) has moved higher as of late, but there could definitely be trouble on the horizon for this company
- PR Newswire
Dr. Stephen Hahn, 24th US FDA Commissioner and Former Chief Medical Executive at MD Anderson, joins Flagship Pioneering as Chief Medical Officer of Flagship's Preemptive Medicine and Health Security Initiative
Flagship Pioneering, the bioplatform innovation company, announced today that Stephen Hahn, M.D. will help lead its Preemptive Medicine and Health Security initiative as Chief Medical Officer, and join Flagship's Senior Leadership Team, effective June 16, 2021. Dr. Hahn served as the U.S. Food and Drug Administration Commissioner from 2019–2021. Prior to joining the FDA, he was the Chief Medical Executive, The University of Texas MD Anderson Cancer Center.
- Zacks
Why Is Denali Therapeutics Inc. (DNLI) Up 10.7% Since Last Earnings Report?
Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
© 2021 Verizon Media. All rights reserved.
